Zomedica Corp. (ZOM)
Stock Price:
$0.0712 USD
-0.0029 (-3.91%)
Updated Oct 28, 2020 11:03 AM EDT - Market open
Key Info
| Market Cap |
40.16M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-13.46M |
| Shares Out |
564.05M |
| EPS (ttm) |
-0.11 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$0.0712 |
| Previous Close |
$0.0741 |
| Change ($) |
-0.0029 |
| Change (%) |
-3.91% |
| Day's Open |
0.0720 |
| Day's Range |
0.0704 - 0.0730 |
| Day's Volume |
6,185,879 |
| 52-Week Range |
0.0700 - 0.4990 |
More Stats
| Market Cap |
40.16M |
| Enterprise Value |
12.51M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
564.05M |
| Float |
538.58M |
| EPS (basic) |
-0.10 |
| EPS (diluted) |
-0.11 |
| FCF / Share |
-0.06 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
17.30M |
| Short Ratio |
0.66 |
| Short % of Float |
3.21% |
| Beta |
-0.28 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.43 |
| Revenue |
n/a |
| Operating Income |
-13.40M |
| Net Income |
-13.46M |
| Free Cash Flow |
-12.74M |
| Net Cash |
27.65M |
| Net Cash / Share |
0.05 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-39.47% |
| ROE |
-72.25% |
| ROIC |
-632.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
0.50
Current: $0.0712
High
0.50
Target: 0.50
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -19.79 | -16.65 | -8.08 | -5.73 |
| Net Income | -19.78 | -16.65 | -8.07 | -5.74 |
| Shares Outstanding | 106 | 93.44 | 87.40 | 80.16 |
| Earnings Per Share | -0.19 | -0.18 | -0.09 | -0.07 |
| Operating Cash Flow | -15.63 | -11.15 | -7.09 | -4.56 |
| Capital Expenditures | -0.16 | -0.62 | -0.17 | -0.23 |
| Free Cash Flow | -15.79 | -11.77 | -7.26 | -4.79 |
| Cash & Equivalents | 0.51 | 1.94 | 3.45 | 3.23 |
| Total Debt | - | - | - | 0.01 |
| Net Cash / Debt | 0.51 | 1.94 | 3.45 | 3.22 |
| Assets | 4.18 | 6.03 | 5.22 | 4.58 |
| Liabilities | 2.09 | 2.38 | 0.83 | 0.74 |
| Book Value | 2.10 | 3.66 | 4.39 | 3.83 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Zomedica Corp. |
| Country |
United States |
| Employees |
28 |
| CEO |
Robert Cohen |
Stock Information
| Ticker Symbol |
ZOM |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NYSEAMERICAN: ZOM |
Description
Zomedica, a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.